Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.

• Tác giả: Seth J Baum, Barry A Borlaug, Karla C Hurt, Chisom Kanu, Christopher M Kramer, Sheldon E Litwin, Venu Menon, Masahiro Murakami, Yang Ou, Milton Packer, Govinda J Weerakkody, Michael R Zile
• Ngôn ngữ: eng
• Ký hiệu phân loại: 809.008 History and description with respect to kinds of persons
• Thông tin xuất bản: United States : Circulation , 2025
• Bộ sưu tập: NCBI
• ID: 688825

Tóm tắt

 BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m RESULTS: Patients were 65.2±10.7 years of age
  53.8% (n=393) were female
  body mass index was 38.2±6.7 kg/m CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains
  enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being
  and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov
  Unique identifier: NCT04847557.